Skip to content

Inhaler technique, adherence and self-management

TL;DR — A prescribed inhaler is not a delivered dose. Device errors are frequent, adherence is often intermittent, and self-report commonly overestimates use. The practical sequence is to observe technique with the patient’s own device, distinguish intentional from unintentional nonadherence, simplify and agree the regimen, and provide a personalized written action plan backed by regular review. Education reduces critical inhaler errors (RR 0.28, 95% CI 0.17–0.47), while supported self-management reduces hospitalization (RR 0.64, 0.50–0.82) and emergency visits (RR 0.82, 0.73–0.94) (Marko 2025, PMID 40102397; Gibson 2003, PMID 12535399). Digital monitoring improves measured adherence on average, but clinical outcomes and durability are inconsistent; it should support, not replace, a therapeutic relationship.

Three different failures

Failure What happens How to detect First response
Technique failure Medication is actuated but little reaches the lung Direct observation against a device-specific checklist Demonstrate, teach-back, recheck
Implementation failure Correct regimen is not taken as agreed Nonjudgmental history, refill data, dose counter or electronic monitor Explore cause and co-design a feasible regimen
Self-management failure Deterioration is recognized late or acted on inconsistently Ask the patient to explain what they would do tomorrow if worse Written action plan, rehearsal and access plan

These failures overlap but are not interchangeable. Increasing dose cannot correct an empty inhaler, an unaffordable prescription, or a breath maneuver that fails to aerosolize or inhale the drug.

Inhaler technique

A meta-analysis found overall device-error rates of 50–100% and critical-error rates of 14–92% across studies and devices, with heterogeneity generally above 90%; the evidence did not support declaring one device universally easiest (Chrystyn 2017, PMID 28373682). A separate review catalogued 299 descriptions of “critical” error, illustrating how inconsistent definitions impede comparison (Usmani 2018, PMID 29338792).

Device-specific checkpoints

Device Essential maneuver Frequent failure Practical correction
Pressurized MDI Slow, deep inhalation coordinated with actuation; breath hold Actuating before/after inspiration; inhaling too fast Spacer when appropriate; one actuation at a time; coached slow breath
Breath-actuated MDI Adequate inspiratory trigger with correct preparation Failure to prime/load or seal lips Demonstrate preparation and audible/visual trigger
Dry-powder inhaler Forceful, deep inhalation after loading Weak inspiratory effort; exhaling into device Keep device dry; exhale away; assess ability to generate flow
Soft-mist inhaler Slow, deep inhalation synchronized with mist Incorrect assembly/priming; poor coordination Reassemble and teach with checklist
Nebulizer Correct interface and adequate treatment time Poor mask seal; stopping early Optimize fit, cleaning and duration

The clinically relevant question is whether the error materially reduces deposition. Reviews associate critical errors with worse control, exacerbations and health-resource use, but much of the evidence is observational and definitions differ (Kocks 2018, PMID 30446655; Roche 2022, PMID 36063773).

In a cross-sectional study of 145 adults, 70% made at least one error; technique differed by device and correlated with outcomes, but causal direction cannot be established from this design (Janežič 2020, PMID 30915886).

Children commonly have poor technique, with better performance using an MDI plus spacer than an MDI alone; counseling improves performance but should include the caregiver and be repeated as responsibility shifts to the child (Gillette 2016, PMID 27130811). Advancing age is also associated with more errors, making dexterity, cognition, vision and inspiratory flow part of device selection (Barbara 2017, PMID 29212836).

Education works, but decays

Education after an error assessment reduced critical errors by 72% in pooled evidence (RR 0.28, 95% CI 0.17–0.47); any incorrect use also fell for dry-powder devices (RR 0.38, 0.21–0.70) and MDIs (RR 0.16, 0.11–0.23) (Marko 2025, PMID 40102397).

The Cochrane evidence found improved technique with enhanced face-to-face training and multimedia approaches, but confidence in downstream exacerbation and quality-of-life effects was lower (Normansell 2017, PMID 28288272). A simple pharmacist intervention improved technique and asthma outcomes, supporting opportunistic checks outside specialist clinics (Basheti 2007, PMID 17433831).

Use a short closed loop:

  1. ask the patient to show, without prompting, exactly how the inhaler is used;
  2. identify the one or two dose-critical errors;
  3. demonstrate the correct sequence;
  4. ask for teach-back on the patient’s own device;
  5. document the device and remaining error;
  6. recheck at the next encounter and after every device change.

Adherence is a behavior, not a trait

ICS adherence in a systematic review averaged 22–63%. Associations with adherence and outcomes varied, and estimates attributing events to poor adherence were observational rather than proof that every missed dose caused an event (Bårnes 2015, PMID 25118311).

Pattern Typical mechanism Useful response
Intentional nonadherence Concern about steroids, low perceived need, stigma, preference Elicit beliefs; give absolute benefit/harm estimates; shared decision
Unintentional nonadherence Forgetting, complex regimen, poor routine Simplify dosing; cue to routines; reminders if wanted
Structural nonadherence Cost, pharmacy access, stock-outs, insurance, transport Choose accessible formulation; longer supply; assistance pathway
Erratic symptom-driven use Controller stopped when well and restarted late Explain prevention; action plan; consider evidence-based combined reliever regimen
Apparent adherence Self-report or prescription overstates ingestion Triangulate refill, counter, biomarker and monitoring data

Language matters. “How many doses did you miss last week?” usually elicits more useful information than “You take this every day, right?” A missed-dose discussion should diagnose friction, not adjudicate virtue.

Measuring adherence

Measure Strength Limitation
Nonjudgmental recall Immediate and inexpensive Recall and social-desirability bias
Validated questionnaire Standardized barrier screen Usually overestimates actual dosing
Pharmacy refill ratio Scalable longitudinal availability Collection is not inhalation; fragmented pharmacies distort data
Dose counter/canister weight Shows use or depletion Dumping and technique are invisible
Electronic monitor Time-stamped actuation; can enable feedback Cost, technical failure, surveillance burden; actuation is not deposition
FeNO suppression under observed ICS Tests steroid-responsive signal in selected type-2-high disease Not a universal adherence test; biology and exposure confound response

In an inner-city cohort, self-report overestimated electronically measured adherence, reinforcing the value of objective triangulation when escalation is contemplated (Sun 2023, PMID 36343353). In type-2-high difficult asthma, suppression of elevated FeNO during monitored ICS can reveal corticosteroid responsiveness and previously unrecognized nonadherence, potentially preventing inappropriate biologic escalation (Butler 2021, PMID 33369570).

Interventions designed to improve ICS adherence produce better adherence more consistently than they produce fewer attacks. Cochrane synthesis found heterogeneous interventions and variable clinical effects (Normansell 2017, PMID 28417456). Pediatric interventions had a small-to-moderate immediate effect, Hedges g 0.39 (95% CI 0.24–0.54), but follow-up evidence was imprecise, g 0.38 (−0.08 to 0.83) (Fidler 2021, PMID 34343294).

Pharmacist-led adult interventions produced a medium pooled adherence effect, standardized mean difference 0.49 (95% CI 0.35–0.64), although intervention content and adherence measures differed (Mes 2018, PMID 29976652).

Personalized action plans

A written action plan should be personalized, understandable and rehearsed. It is not a generic leaflet.

Zone Patient-facing content
Stable Usual controller/reliever, personal control goals and trigger management
Deteriorating Specific symptom or peak-flow threshold; reliever and controller changes; review timing
Urgent Danger signs, maximum interim reliever instructions, emergency contact and destination

The effective package combines education, self-monitoring, a written plan and regular professional review. Across 36 trials, this reduced hospitalizations (RR 0.64, 95% CI 0.50–0.82), emergency visits (RR 0.82, 0.73–0.94), unscheduled clinician visits (RR 0.68, 0.56–0.81), and work/school absence (RR 0.79, 0.67–0.93) (Gibson 2003, PMID 12535399).

A meta-review spanning 27 reviews and 244 RCTs found benefits across demographic and health-system settings; patient education, an action plan and regular professional review were the core components, and costs were offset in part by lower hospitalization and emergency use (Pinnock 2017, PMID 28302126).

Action plans used in isolation have a less certain evidence base than supported self-management as a system. Adult action-plan trials were heterogeneous in plan content, co-interventions and outcomes (Gatheral 2017, PMID 28394084). Implementation therefore requires trained clinicians, time, accessible formats and organizational ownership (Pinnock 2015, PMID 26306110).

Shared decisions and health literacy

Shared decision-making means exchanging evidence and preferences and reaching an agreed plan. A Cochrane review found too few heterogeneous trials for confident conclusions across all outcomes, so it should not be reduced to a scripted consent exercise (Kew 2017, PMID 28972652).

Plans should use the patient’s preferred language, concrete dose instructions, pictures when useful, and teach-back. Confirm who manages medication at home, school and work. Device selection should consider capability, preference, dose availability, environmental footprint, portability and recurring cost—not marketing familiarity alone.

Digital support

A Cochrane review included 40 RCTs and 15,207 participants. Digital interventions improved adherence, particularly electronic monitoring with reminders, but studies differed in platforms, duration and bias; exacerbation and control effects were less consistent than adherence effects (Chan 2022, PMID 35691614).

Electronic monitoring devices improved adherence over more than three months, random-effects SMD 0.41 (95% CI 0.22–0.60). ACT improvement was uncertain under random effects, SMD 0.47 (−0.14 to 1.08) (Garin 2023, PMID 36986513).

A pediatric RCT improved ACT by an adjusted 2.2 points versus control but unexpectedly recorded more emergency visits and hospitalizations, showing that a favorable control score is not enough to establish net benefit (Gupta 2021, PMID 33386336).

The 12-month ACCEPTANCE primary-care trial tested feedback and reminders against passive monitoring in adults with suboptimal control and adherence; its long-term, cluster design addresses durability better than short pilots, but open-label behavior and device-specific implementation remain considerations (PMID 40118212). A remote RCT of a commercial self-management platform also illustrates the need to distinguish app engagement and short-term ACT change from attacks, equity and sustained benefit (Kandola 2024, PMID 38684084).

Remote-monitoring trials remain diverse in population, intervention and outcomes; synthesis should separate reminders, clinician dashboards, technique sensors and broader telehealth rather than treating “digital” as one intervention (Mosnaim 2025, PMID 40107660).

Digital safeguards should include consent, data minimization, a clear response protocol, accessibility without a new smartphone, and an explicit statement that alerts are not emergency monitoring.

Children, schools and transitions

School-based self-management programs reduced emergency-department visits (OR 0.70, 95% CI 0.53–0.92) and modestly reduced hospitalization (SMD −0.19, −0.35 to −0.04) in meta-analysis, though program components and settings varied (Kneale 2019, PMID 30686788). Programs can improve access and peer normalization, but require consent, rescue-medication availability and coordination with caregivers and clinicians (Harris 2019, PMID 31422031).

Responsibility should transfer gradually in adolescence. The young person should demonstrate technique, know the plan and carry/access reliever medication, while caregivers retain appropriate oversight until competence and reliability are established.

A review checklist

At every review After an attack Before step-up/biologic referral
Observe technique Reconstruct symptom and medication timeline Reconfirm diagnosis and phenotype
Ask about missed doses and barriers Identify delay in action plan Obtain objective adherence evidence
Check prescription access and counters Replace used/expired medication Observe every prescribed device
Review reliever frequency Revise and rehearse written plan Address access, exposure and comorbidity
Agree one feasible change Arrange time-defined follow-up Avoid labeling behavior as “refractory” biology

Open questions

  • Which adherence intervention components reduce severe attacks rather than only device-recorded actuations? (Chan 2022, PMID 35691614)
  • How long do technique gains persist, and what recheck interval is efficient across devices and ages? (Marko 2025, PMID 40102397)
  • Can privacy-preserving monitors distinguish inhalation quality from actuation without worsening access inequity?
  • What is the best method for identifying intentional, unintentional and structural nonadherence in routine practice?
  • Which implementation strategies make supported self-management routine at health-system scale? (Pinnock 2017, PMID 28302126)

References

  1. Usmani OS, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018. PMID 29338792
  2. Chrystyn H, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017. PMID 28373682
  3. Kocks JWH, et al. Association between critical errors in inhalation and health outcomes: systematic review. NPJ Prim Care Respir Med. 2018. PMID 30446655
  4. Roche N, et al. Impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: systematic review. J Allergy Clin Immunol Pract. 2022. PMID 36063773
  5. Janežič A, et al. Inhalation technique and asthma outcomes with corticosteroid-containing devices. J Asthma. 2020. PMID 30915886
  6. Gillette C, et al. Inhaler technique in children with asthma: systematic review. Acad Pediatr. 2016. PMID 27130811
  7. Barbara S, et al. Inhaler technique: does age matter? Systematic review. Eur Respir Rev. 2017. PMID 29212836
  8. Marko M, et al. Inhalation errors after education: systematic review and meta-analysis. Sci Rep. 2025. PMID 40102397
  9. Normansell R, et al. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev. 2017. PMID 28288272
  10. Basheti IA, et al. Improved asthma outcomes with a simple inhaler-technique intervention by community pharmacists. J Allergy Clin Immunol. 2007. PMID 17433831
  11. Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids. Respir Care. 2015. PMID 25118311
  12. Sun Y, et al. Measurement of ICS adherence by self-report and electronic monitoring. Clin Exp Allergy. 2023. PMID 36343353
  13. Butler CA, et al. Fractional exhaled nitric oxide and asthma treatment adherence. Curr Opin Pulm Med. 2021. PMID 33369570
  14. Normansell R, et al. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017. PMID 28417456
  15. Fidler A, et al. Meta-analysis of adherence-promotion interventions in pediatric asthma. J Pediatr Psychol. 2021. PMID 34343294
  16. Mes MA, et al. Pharmacists and medication adherence in asthma: systematic review and meta-analysis. Eur Respir J. 2018. PMID 29976652
  17. Gibson PG, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003. PMID 12535399
  18. Pinnock H, et al. Systematic meta-review of supported self-management for asthma. BMC Med. 2017. PMID 28302126
  19. Gatheral TL, et al. Personalised asthma action plans for adults with asthma. Cochrane Database Syst Rev. 2017. PMID 28394084
  20. Pinnock H. Supported self-management for asthma. Breathe. 2015. PMID 26306110
  21. Kew KM, et al. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017. PMID 28972652
  22. Chan A, et al. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022. PMID 35691614
  23. Garin N, et al. Clinical impact of electronic inhaler-monitoring devices: systematic review and meta-analysis. Pharmaceuticals. 2023. PMID 36986513
  24. Gupta RS, et al. Sensor-based electronic monitoring for asthma: randomized controlled trial. Pediatrics. 2021. PMID 33386336
  25. van de Hei SJ, et al. Long-term effectiveness of a digital inhaler: ACCEPTANCE trial. J Allergy Clin Immunol Pract. 2025. PMID 40118212
  26. Kandola A, et al. Digital self-management platform for adult asthma: randomized trial. JMIR Mhealth Uhealth. 2024. PMID 38684084
  27. Mosnaim G, et al. Remote monitoring in asthma: a systematic review. J Allergy Clin Immunol Pract. 2025. PMID 40107660
  28. Kneale D, et al. School-based self-management interventions for asthma: Cochrane review and meta-analysis. Thorax. 2019. PMID 30686788
  29. Harris K, et al. School-based asthma self-management interventions for children and adolescents. Cochrane Database Syst Rev. 2019. PMID 31422031